Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: A meta-analysis

Journal of Viral Hepatitis

Volumn 22, Issue 10, 2015, Pages 842-849

  Mozessohn, Lee ^a   Chan, K K W ^b   Feld, J J ^c   Hicks, L K ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

hepatitis B; hepatitis B reactivation; non Hodgkin's lymphoma; rituximab

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RITUXIMAB; VIRUS DNA; ANTINEOPLASTIC AGENT; HEPATITIS B ANTIBODY;

ARTICLE; DRUG SAFETY; HEPATITIS B; HUMAN; INFECTION RISK; LYMPHOMA; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; VIRUS REACTIVATION; BLOOD; COMPLICATION; DRUG EFFECTS; HEPATITIS B VIRUS; VIRUS ACTIVATION;

ANTINEOPLASTIC AGENTS; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LYMPHOMA; RISK ASSESSMENT; RITUXIMAB; VIRUS ACTIVATION;

EID: 84941190611     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12402     Document Type: Article

References (51)

1. Coiffier B, Thieblemont C, Van Den Neste E, et al,. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116 (12): 2040-2045.
2. Marcus R, Imrie K, Solal-Celigny P, et al,. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26 (28): 4579-4586.
3. Schulz H, Bohlius JF, Trelle S, et al,. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99 (9): 706-714.
4. Edwards JC, Szczepanski L, Szechinski J, et al,. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350 (25): 2572-2581.
5. Cohen SB, Emery P, Greenwald MW, et al,. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54 (9): 2793-2806.
6. Maloney DG,. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 366 (21): 2008-2016.
7. Lavanchy D,. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11 (2): 97-107.
8. Liu CJ, Chen DS, Chen PJ,. Epidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT. J Clin Virol 2006; 36 (Suppl. 1): S33-S44.
9. Uhm JE, Kim K, Lim TK, et al,. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13 (4): 463-468.
10. Hsu C, Tsou HH, Lin SJ, et al,. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59 (6): 2092-2100.
11. Huang YH, Hsiao LT, Hong YC, et al,. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31 (22): 2765-2772.
12. Li L, Chen PJ, Chen MH, Chak KF, Lin KS, Tsai SJ,. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus. Transfusion 2008; 48 (6): 1198-1206.
13. Hui CK, Sun J, Au WY, et al,. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42 (6): 813-819.
14. Zhu Y, Yamamoto T, Cullen J, et al,. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75 (1): 311-322.
15. Zurawska U, Hicks LK, Woo G, et al,. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012; 30 (26): 3167-3173.
16. Lau GK, Yiu HH, Fong DY, et al,. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125 (6): 1742-1749.
17. Hsu C, Hsiung CA, Su IJ, et al,. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008; 47 (3): 844-853.
18. Loomba R, Rowley A, Wesley R, et al,. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148 (7): 519-528.
19. Coffin CS, Fung SK, Ma MM,. Canadian Association for the Study of the L. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines. Can J Gastroenterol 2012; 26 (12): 917-938.
20. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Non-Hodgkin's Lymphomas Version 2.2013. Available at: http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf (accessed 15 December 2013).
21. Lok ASF, McMahon BJ,. Chronic Hepatitis B: Update 2009. American Association for the Study of Liver Diseases. Available at: http://www.aasld.org (accessed 15 December 2013).
22. "Arzerra (ofatumumab) and Rituxan (rituximab): Drug Safety Communication-New Boxed Warning, Recommendations to Decrease Risk of Hepatitis B Reactivation". Available at: http://www.fda.gov (accessed 15 October 2013).
23. "Recommendations for Routine Testing and Follow-up for Chronic Hepatitis B Virus (HBV) Infection". Available at: http://www.cdc.gov (accessed 10 January 2014).
24. Lalazar G, Rund D, Shouval D,. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136 (5): 699-712.
25. Liang R,. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113 (14): 3147-3153.
26. Chen PM, Fan S, Liu CJ, et al,. Changing of hepatitis B virus markers in patients with bone marrow transplantation. Transplantation 1990; 49 (4): 708-713.
27. Onozawa M, Hashino S, Izumiyama K, et al,. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79 (5): 616-619.
28. Wu JM, Huang YH, Lee PC, Lin HC, Lee SD,. Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma. J Clin Gastroenterol 2009; 43 (5): 496-498.
29. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM,. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005; 46 (7): 1085-1089.
30. Dervite I, Hober D, Morel P,. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344 (1): 68-69.
31. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7 (3): 177-188.
32. Available at: http://www.cebm.brown.edu/open-meta (accessed April 30, 2014).
33. Francisci D, Falcinelli F, Schiaroli E, et al,. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010; 38 (1): 58-61.
34. Fukushima N, Mizuta T, Tanaka M, et al,. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20 (12): 2013-2017.
35. Hanbali A, Khaled Y,. Incidence of hepatitis B reactivation following Rituximab therapy. Am J Hematol 2009; 84 (3): 195.
36. Ji D, Cao J, Hong X, et al,. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 2010; 85 (3): 243-250.
37. Koo YX, Tay M, Teh YE, et al,. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol 2011; 90 (10): 1219-1223.
38. Matsue K, Kimura SI, Takanashi Y, et al,. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer 2010; 116 (20): 4769-4776.
39. Mendez-Navarro J, Corey KE, Zheng H, et al,. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011; 31 (3): 330-339.
40. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N,. Prospec-tive analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol 2010; 28 (34): 5097-5100.
41. Oh MJ, Lee HJ,. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Clin Mol Hepatol 2013; 19 (1): 51-59.
42. Persico E, De Renzo A, La Mura V, et al,. Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients. Gut 2007; 56 (10): 1470-1471.
43. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E,. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008; 93 (6): 951-952.
44. Yeo W, Chan TC, Leung NWY, et al,. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27 (4): 605-611.
45. Zhu JY, Chen FY, Xiao F, et al,. Clinical analysis of prophylactic lamivudine reduced hepatitis B virus reactivation in patients with B-cell non-Hodgkin's lymphoma receiving rituximab combination chemotherapy. J Leuk Lymphoma 2012; 21 (9): 524-527.
46. Watanabe M, Shibuya A, Tsunoda Y, et al,. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection. Liver Int 2011; 31 (3): 340-347.
47. Evens AM, Jovanovic BD, Su YC, et al,. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22 (5): 1170-1180.
48. "ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases". Available at: http://www.asco.org (accessed 15 January 2014).
49. Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Available at: http://www.eortc.be/services/doc/ctc/ (accessed May 22, 2014).
50. Pujol FH, Navas MC, Hainaut P, Chemin I,. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett 2009; 286 (1): 80-88.
51. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y,. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol 2013; 57 (3): 209-214.